Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 12, 2004. The report details specific corporate actions regarding director share interests and a share buyback program executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2004.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share transactions:
- Director Share Purchase: 363 American Depository Shares (ADS) purchased for Dr. L. Shapiro at $39.21 per share on August 11, 2004.
- Share Buyback: 1,000,000 Ordinary shares purchased on August 11, 2004, at 1,065.62 pence per share.
Material Changes
The primary material change reported is the reduction of outstanding shares through a treasury buyback. Following the purchase of 1,000,000 shares, the Company holds 32,718,000 shares in Treasury. The total number of shares in issue (excluding Treasury shares) stands at 5,901,326,401.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (32,718,000) against subsequent filings.
- Confirm the total shares in issue (5,901,326,401) excluding Treasury shares.
- Review the terms of the GlaxoSmithKline Scientific Advisory Board Share Allocation Plan regarding Dr. Shapiro's holdings.
- Check for any additional buyback activity under the authority granted on May 17, 2004.